SynthesisFrontiers in pharmacology2025
Triterpenes in breast cancer: a systematic review of preclinical evidence in rodents.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer poses a significant health problem for women worldwide due to late-stage diagnosis, toxicity of standard therapy and drug resistance. Several therapeutic alternatives, including triterpenes, show promising therapeutic potential and reduced toxicity Methodology: We aimed to systematically review the data provided by rodent models of breast cancer regarding the anticancer effect, mechanisms of action and safety of triterpenes to assess if clinical translation to human studies is supported by current evidence. After a two-phase screening process, our search of PubMed/Medline, Web of Science (WOS) and Scopus databases yielded 163 articles that were included in the analysis. Results and discussions: Triterpenes were used in free form, semisynthetic derivatives (triterpenoids), cotreatment with other drugs or formulated as liposomes, micelles and nanoparticles (NPs). The vote-counting analysis showed a superior effect of triterpenes compared to controls in terms of tumor volume and weight reduction, findings also confirmed by a sensitivity analysis. We also searched for possible sources of heterogeneity in the studies assessed by analyzing several subgroups, which provided valuable information. They exerted their effect through various mechanisms such as apoptosis induction, metastasis and angiogenesis inhibition and decreased several cancer biomarkers such as ki-67, proliferating cell nuclear antigen (PCNA) and matrix metalloproteinases (MMP). The toxicity assessment revealed that triterpenes have in general, insignificant or absent toxicity, with only a small number of studies reporting serious side effects such as leukopenia, hepatotoxicity and mortality at specific doses that were reversed in some cases by the use of carriers, which hold the potential to enhance the therapeutic effect of triterpenes while reducing their systemic toxicity. Conclusion: We concluded that the current
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.